fludarabine has been researched along with Adverse Drug Event in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S | 1 |
| Schmidt, C | 1 |
| Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C | 1 |
| Canales, M; de la Serna, J; de Oña, R; de Sevilla, AF; Martínez, R; Martínez-López, J; Montalbán, C; Paz-Carreira, J; Rapado, I; Rivero, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Bajo, R; Burgaleta, C; Caballero, MD; Canales, M; De La Serna, J; De Oña, R; De Sevilla, AF; Díaz, N; Martínez, R; Martínez-López, J; Montalbán, C; Peñalver, J; Prieto, E; Queizán, JA; Salar, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Argentieri, D; Bartomioli, M; Bezares, RF; Diaz, A; Garay, G; Milone, G; Ryser, R; Stemelin, G; Zubiaur, EL | 1 |
| Andersohn, F; Bronder, E; Garbe, E; Grüneisen, A; Hildebrandt, M; Klimpel, A; Kurtal, H; Mayer, B; Salama, A; Schrezenmeier, H; Späth-Schwalbe, E; Thomae, M | 1 |
| Bahlo, J; Böttcher, S; Bühler, A; Busch, R; Cramer, P; Döhner, H; Eckart, MJ; Eichhorst, BF; Elter, T; Fischer, K; Goede, V; Hallek, M; Kiehl, M; Kneba, M; Kranz, G; Schweighofer, CD; Staib, P; Stilgenbauer, S; Wendtner, CM; Winkler, D | 1 |
| Bairey, O; Berrebi, A; Lugassy, G; Polliack, A; Rahimi-Levene, N; Shpilberg, O; Shtalrid, M; Shvidel, L | 1 |
| Cordonnier, M | 1 |
| Arai, Y; Doki, N; Ishida, F; Kano, Y; Kawai, Y; Komatsu, N; Miyawaki, S; Morii, T; Ogura, M; Ohno, R; Takeshita, A; Usui, N | 1 |
4 trial(s) available for fludarabine and Adverse Drug Event
| Article | Year |
|---|---|
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cooperative Behavior; Cyclophosphamide; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoadjuvant Therapy; Rituximab; Spain; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Cytomegalovirus Infections; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Pilot Projects; Salvage Therapy; Survival Analysis; Vidarabine | 2011 |
Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Intention to Treat Analysis; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Nitrogen Mustard Compounds; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2011 |
Phase I trial of FLAGM with high doses of cytosine arabinoside for relapsed, refractory acute myeloid leukemia: study of the Japan Adult Leukemia Study Group (JALSG).
Topics: Adult; Cytarabine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Recurrence; Vidarabine | 2007 |
9 other study(ies) available for fludarabine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Iran; Male; Middle Aged; Prognosis; Quality of Life; Retrospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2021 |
The struggle to do no harm in clinical trials.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD19; Child; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Inflammation; Lenalidomide; Male; Neoplasms; Nivolumab; Prognosis; Programmed Cell Death 1 Receptor; Risk Management; T-Lymphocytes; Thalidomide; Treatment Outcome; Vidarabine | 2017 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine Kinase; DNA Mutational Analysis; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Vidarabine | 2011 |
Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Berlin; beta-Lactams; Case-Control Studies; Ciprofloxacin; Diclofenac; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lorazepam; Male; Middle Aged; Odds Ratio; Piperacillin; Population Surveillance; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine; Young Adult | 2011 |
Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2003 |
[Visual cortes--is it a concern?].
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Blindness, Cortical; Carmustine; Cathartics; Cholinergic Antagonists; Cisplatin; Cyclosporine; Dopamine Agents; Drug-Related Side Effects and Adverse Reactions; Hallucinations; Humans; Interferons; Serotonin Agents; Tacrolimus; Vidarabine; Vincristine; Visual Cortex | 2007 |